{"id":"NCT02197416","sponsor":"Boehringer Ingelheim","briefTitle":"Safety of Dabigatran Etexilate in Blood Clot Prevention in Children","officialTitle":"Open Label, Single Arm Safety Prospective Cohort Study of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Children From 0 to Less Than 18 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-29","primaryCompletion":"2019-10-16","completion":"2019-11-19","firstPosted":"2014-07-22","resultsPosted":"2020-06-04","lastUpdate":"2020-06-04"},"enrollment":214,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism","Secondary Prevention"],"interventions":[{"type":"DRUG","name":"dabigatran etexilate","otherNames":[]}],"arms":[{"label":"dabigatran etexilate","type":"EXPERIMENTAL"}],"summary":"This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients. Children from 0 to less than 18 years of age will be eligible to participate.","primaryOutcome":{"measure":"Event-free Probability of Recurrence of Venous Thromboembolism (VTE) at 6 and 12 Months","timeFrame":"At month 6 (Week 26) and 12 (Week 52) of on treatment period","effectByArm":[{"arm":"Dabigatran Etexilate (0 to < 2 Years)","deltaMin":1,"sd":null},{"arm":"Dabigatran Etexilate (2 to <12 Years)","deltaMin":1,"sd":null},{"arm":"Dabigatran Etexilate (12 to <18 Years)","deltaMin":0.979,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":62,"countries":["United States","Austria","Belgium","Brazil","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Lithuania","Mexico","Norway","Russia","Sweden","Switzerland","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["38348778","36150047","31805182"],"seeAlso":["https://trials.boehringer-ingelheim.com/"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":213},"commonTop":["Nasopharyngitis","Headache","Nausea","Diarrhoea","Dyspepsia"]}}